Drug profile · INN
penbutolol sulfate
LEVATOL
penbutolol sulfate (LEVATOL) is a beta-1 adrenergic receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Drug details — penbutolol sulfate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
penbutolol sulfate (LEVATOL) is a beta-1 adrenergic receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Beta-1 adrenergic receptor antagonist
Primary target: Beta-1 adrenergic receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is penbutolol sulfate?
penbutolol sulfate (LEVATOL) is a beta-1 adrenergic receptor antagonist. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for penbutolol sulfate?
LEVATOL is a marketed brand name for penbutolol sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of penbutolol sulfate?
penbutolol sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.